Inflammation Mediators

Inflammation mediators are signaling molecules released by immune cells and tissues in response to injury, infection, or irritation. They include cytokines (e.g., TNF-α, IL-1, IL-6), chemokines, prostaglandins, leukotrienes, and histamine. These mediators regulate the inflammatory response by increasing blood flow, recruiting immune cells to the site of damage, and promoting tissue repair. Understanding their role is essential for developing anti-inflammatory therapies and managing chronic inflammatory diseases.

Common inflammation mediators used in biomedical research include tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), prostaglandin E2 (PGE2), and leukotriene B4 (LTB4). These biomarkers help scientists study inflammatory pathways, screen potential drug candidates, and evaluate the efficacy of anti-inflammatory compounds in vitro and in vivo models.

Inflammation mediators serve as critical therapeutic targets in drug development for conditions like rheumatoid arthritis, asthma, inflammatory bowel disease (IBD), and psoriasis. By inhibiting specific mediators—such as blocking TNF-α with monoclonal antibodies—pharmaceutical researchers can modulate the immune response and reduce chronic inflammation. High-purity inflammation mediator standards are also essential for assay validation and pharmacokinetic studies during preclinical and clinical trials.

Yes, certain inflammation mediators—such as C-reactive protein (CRP), IL-6, and TNF-α—are widely used as clinical biomarkers to assess the presence and severity of inflammation. Elevated levels in serum or plasma can indicate acute infections, autoimmune disorders, or chronic inflammatory conditions. Their quantification aids in diagnosis, treatment monitoring, and prognosis evaluation in both research and clinical settings.